<DOC>
	<DOC>NCT01997944</DOC>
	<brief_summary>This is an open label study that will be conducted at a single site in China to evaluate the safety,tolerability and PK/PD profile of multiple dose of recombinant human serum albumin/interferon alpha2a fusion protein in chronic hepatitis B patients.The total duration of study participation is up to 22 weeks for each subject,including 4 weeks screening period.</brief_summary>
	<brief_title>Recombinant Human Serum Albumin/Interferon alpha2a Fusion Protein Phase Ib Study in Chronic Hepatitis B Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Male or female, aged 1875 years Chronic HBV infection (serum HBsAg detectable for &gt; 6 months) Serum HBeAg positive with HBV DNA &gt;10^6copies/mL (or &gt;20,000 IU/mL),orSerum HBeAg negative with HBV DNA &gt;10^5copies/mL (or &gt;2,000 IU/mL) Serum ALT must be &gt; 2 x ULN but below 10 x ULN Steroid treatment or immunosuppression 3 months prior to entry. Interferon therapy or nucleotides analogues therapy in 6 months prior to entry. Active lung disease or history of interstitial lung disease. Hb&lt; LLN or, and ANC &lt; 750/mm3 or , and platelet count &lt; 75,000 mm3 ,or WBC&lt;3000/mm3 . Significant chronic medical conditions other than chronic hepatitis B which in the opinion of the investigator preclude enrollment into the study. Evidence of hepatic decompensation (i.e., ChildPugh score of B or C). Seropositive for HIV, HCV, or HDV (Hepatitis Delta virus). History of thyroid disease or current treatment for thyroid disease. Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>